We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$524M
1-Year Est. Return
164.42%
This Fund
S&P 500
This Quarter
Est. Return
+13.31%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$118M
AUM Growth
+$4.41M
(+3.9%)
Cap. Flow
-$8.19M
Cap. Flow
% of AUM
-6.92%
Top 10 Holdings %
Top 10 Hldgs %
44.84%
Holding
84
New
17
Increased
12
Reduced
22
Closed
11
Avg Time Held
5.2
quarters
Top 10 Avg Time Held
4.1
quarters
Top 20 Avg Time Held
4.8
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
LOXO
Loxo Oncology, Inc
LOXO
|
+$6.63M |
| 2 |
BioCryst Pharmaceuticals
BCRX
|
+$3.31M |
| 3 |
Cellectis
CLLS
|
+$1.61M |
| 4 |
Rigel Pharmaceuticals
RIGL
|
+$1.21M |
| 5 |
BioLineRX
BLRX
|
+$1.07M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cytokinetics
CYTK
|
+$2.56M |
| 2 |
AERI
Aerie Pharmaceuticals
AERI
|
+$2.3M |
| 3 |
Dermira, Inc.
DERM
|
+$2.28M |
| 4 |
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$2.21M |
| 5 |
TSRO
TESARO, Inc.
TSRO
|
+$2.08M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.12% |
| 2 | Miscellaneous | 6.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
| $12.7M | 10.7% |
300,722
+161,000
| +115% | +$6.63M |
2015 Q2
7 quarters
|
|
2
AtriCure
ATRC
$2.89B
| $9.71M | 8.21% |
506,946
-12,000
| -2% | -$210K |
2013 Q2
15 quarters
|
|
|
NXTM
3
DELISTED
NxStage Medical Inc.
NXTM
| $5.8M | 4.9% |
216,119
-20,000
| -8% | -$552K |
2013 Q2
15 quarters
|
|
|
ALDR
4
DELISTED
Alder Biopharmaceuticals
ALDR
| $4.6M | 3.89% |
221,013
| – | – |
2015 Q3
6 quarters
|
|
|
5
BioCryst Pharmaceuticals
BCRX
$2.06B
| $4.54M | 3.84% |
541,128
+475,228
| +721% | +$3.31M |
2016 Q4
1 quarter
|
|
6
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $3.56M | 3.01% |
24,787
-7,601
| -23% | -$1.09M |
2016 Q4
1 quarter
|
|
7
DELISTED
Blueprint Medicines
BPMC
| $3.3M | 2.79% |
82,500
+10,000
| +14% | +$358K |
2016 Q4
1 quarter
|
|
|
8
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.9B
| $3.05M | 2.58% |
35,359
-30,709
| -46% | -$2.21M |
2015 Q3
6 quarters
|
|
9
BeOne Medicines Ltd
ONC
$39.5B
| $2.97M | 2.52% |
81,231
-38,610
| -32% | -$1.41M |
2016 Q1
4 quarters
|
|
|
AGTC
10
DELISTED
Applied Genetic Technologies Corporation
AGTC
| $2.84M | 2.4% |
411,000
+124,702
| +44% | +$974K |
2015 Q1
8 quarters
|
|
11
Ardelyx
ARDX
$806M
| $2.81M | 2.37% |
221,738
+47,743
| +27% | +$628K |
2016 Q1
4 quarters
|
|
12
Insulet
PODD
$9.58B
| $2.74M | 2.31% |
63,484
-10,000
| -14% | -$429K |
2013 Q2
15 quarters
|
|
13
Spyre Therapeutics
SYRE
$7.52B
| $2.61M | 2.21% |
14,016
| – | – |
2016 Q2
3 quarters
|
|
14
iShares Biotechnology ETF
IBB
$10.2B
| $2.55M | 2.16% |
26,100
| – | – |
2016 Q4
1 quarter
|
|
15
Neurocrine Biosciences
NBIX
$13.7B
| $2.53M | 2.14% |
58,508
-7,500
| -11% | -$321K |
2016 Q1
4 quarters
|
|
16
MacroGenics
MGNX
$218M
| $2.22M | 1.88% |
119,200
+30,000
| +34% | +$579K |
2015 Q3
6 quarters
|
|
17
DELISTED
BioTelemetry, Inc.
BEAT
| $2.17M | 1.84% |
75,000
| – | – |
2013 Q2
15 quarters
|
|
|
AERI
18
DELISTED
Aerie Pharmaceuticals
AERI
| $2.12M | 1.79% |
46,770
-51,600
| -52% | -$2.3M |
2014 Q3
10 quarters
|
|
|
SPNC
19
DELISTED
Spectranetics Corp
SPNC
| $1.91M | 1.61% |
65,496
| – | – |
2013 Q2
15 quarters
|
|
20
DELISTED
Radius Health, Inc.
RDUS
| $1.89M | 1.6% |
48,809
-5,045
| -9% | -$212K |
2016 Q1
4 quarters
|
|
|
21
Cellectis
CLLS
$111M
| $1.83M | 1.55% |
+76,404
| New | +$1.61M |
2017 Q1
0 quarters
|
|
22
Tvardi Therapeutics
TVRD
$13.9M
| $1.75M | 1.48% |
2,648
-3,172
| -55% | -$1.69M |
2015 Q2
7 quarters
|
|
|
IMMU
23
DELISTED
Immunomedics Inc
IMMU
| $1.63M | 1.38% |
252,574
-307,100
| -55% | -$1.56M |
2016 Q2
3 quarters
|
|
24
DELISTED
Cidara Therapeutics
CDTX
| $1.63M | 1.38% |
10,423
+2,427
| +30% | +$426K |
2016 Q4
1 quarter
|
|
|
FOMX
25
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $1.61M | 1.36% |
325,667
+57,600
| +21% | +$554K |
2015 Q4
5 quarters
|
|
Similar funds
4WM
BB
A
HW
DAM
SDWIA
SCA
BHPW
DAFNA Capital Management's Q1 2017 Portfolio in Review
As of Q1 2017, DAFNA Capital Management held 84 positions worth $118M, up 3.9% from $114M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
DAFNA Capital Management withdrew a net $8.19M in Q1 2017, closing 11 positions and reducing 22 holdings. Its most notable exit was Cytokinetics, an estimated $2.56M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Miscellaneous.
Against the trend, DAFNA Capital Management opened a new position in Cellectis worth $1.83M.
- DAFNA Capital Management's largest Q1 2017 buy was Cellectis: 76,404 shares worth $1.83M.
- DAFNA Capital Management added most to Loxo Oncology, Inc in Q1 2017, an estimated $6.63M increase.
- DAFNA Capital Management's biggest Q1 2017 reduction was Aerie Pharmaceuticals, cutting an estimated $2.3M.
- DAFNA Capital Management fully exited Cytokinetics in Q1 2017, selling an estimated $2.56M.
- DAFNA Capital Management's ten largest holdings make up 45% of its $118M portfolio in Q1 2017.
- DAFNA Capital Management opened 17 new positions and closed 11 in Q1 2017.
- DAFNA Capital Management's portfolio value rose 3.9% quarter-over-quarter to $118M.
Based on DAFNA Capital Management's 13F filing for Q1 2017, filed 15 May 2017.